Jefferies Financial Group Inc. Buys New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Jefferies Financial Group Inc. acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 350,029 shares of the company's stock, valued at approximately $6,787,000. Jefferies Financial Group Inc. owned about 1.00% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics in the 4th quarter worth approximately $54,000. AlphaCentric Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $144,000. Squarepoint Ops LLC bought a new stake in Oruka Therapeutics during the 4th quarter valued at $236,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Oruka Therapeutics during the 4th quarter valued at $303,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Trading Up 3.3%

Shares of ORKA stock traded up $0.38 on Thursday, reaching $11.85. The company's stock had a trading volume of 128,700 shares, compared to its average volume of 224,637. The stock's fifty day simple moving average is $9.75 and its 200-day simple moving average is $13.97. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $31.13. The company has a market capitalization of $443.68 million, a price-to-earnings ratio of -1.89 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ORKA. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Thursday, May 15th. BTIG Research initiated coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics has a consensus rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.